Understanding how bladder cancer cells resist platinum chemotherapy
Official title: Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer
Funded at Dana-Farber Cancer Inst · NIH-11036376 · Data updated 2026-11-12
This study is looking into how bladder cancer cells become resistant to a common chemotherapy treatment, with the goal of finding new ways to help improve outcomes for patients battling this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $725,117 |
| NIH project number | 5R01CA279221-02 |
| Project ID | NIH-11036376 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with muscle-invasive or metastatic bladder cancer who are undergoing platinum-based chemotherapy.
✕Less likely to help
Patients with non-muscle invasive bladder cancer or those who are not receiving platinum-based chemotherapy may not benefit from this research.
What this research studies
This research investigates the mechanisms by which bladder cancer cells develop resistance to platinum-based chemotherapy, a common treatment for muscle-invasive and metastatic bladder cancer. The team will use advanced laboratory models and patient-derived data to explore how changes in the cancer cells and their interactions with immune cells contribute to this resistance. By analyzing these cellular processes, the research aims to identify potential targets for improving treatment outcomes for patients with bladder cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bladder cancer patients who currently do not respond well to platinum chemotherapy.
How similar studies have gone: Previous research has shown promising results in understanding cancer resistance mechanisms, indicating that this approach has the potential for success.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Van Allen, Eliezer M — Dana-Farber Cancer Inst
- Study coordinator: Van Allen, Eliezer M
Related research
Other NIH-funded projects on the same topics.
-
Population modeling to reduce bladder cancer burden
Aimed at predicting and guiding effective, population-based ways to prevent and control bladder cancer.
-
Blocking a new immune checkpoint in bladder cancer
Researchers are trying medicines that block a newly found immune pathway to help people with bladder cancer, especially those whose tumors do not respond to current immunotherapy.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Understanding why bladder cancer spreads and resists treatment
This grant studies how advanced bladder cancer changes and spreads across the body, aiming to uncover why it’s hard to treat.
-
Molecular clues to bladder cancer cell changes and therapy response
This NIH grant looks at how bladder cancer cells change their identity and how that affects response to treatment, with a focus on aggressive neuroendocrine variants.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.